reference/1104031

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1104031

Outgoing Links

Predicate	Object
contentType	Letter\|Research Support, Non-U.S. Gov't
endingPage	2781
issn	0305-7453 1460-2091
issueIdentifier	11
pageRange	2779-2781
publicationName	The Journal of antimicrobial chemotherapy
startingPage	2779
bibliographicCitation	Le MP, Solas C, Garraffo R, Gagnieu M-, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant J, Peytavin G. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor. Journal of Antimicrobial Chemotherapy. 2012 Jul 06;67(11):2779–81. doi: 10.1093/jac/dks260.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d4dab76d3a1c1fb16f9f0fd6db366dc4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de590d2713ccec63dc1735513e41ba59 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a4fa3c8f4081900e0d255b84c27fbebd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b14d303f603436206488d5314b7885e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de7edb1b230165ae90fe9c0af4aa183b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_578f935c93d3e711cf26037381d79638 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c7b2bffe1535b71e3bf3b5e3c977566c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b503e2804fd3f75e1cdf035eb1f1793 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f753595916f686fb7097e8d75d6af6fa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16ad1325b1b1c27d799a60427494b9a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_822b7a8ac2418ae09324c1f227b324a8
date	2012-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/22773742 https://doi.org/10.1093/jac/dks260
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4495 https://portal.issn.org/resource/ISSN/1460-2091 https://portal.issn.org/resource/ISSN/0305-7453
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor
discusses	http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0005469 http://id.nlm.nih.gov/mesh/M0420447 http://id.nlm.nih.gov/mesh/M0028839 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0018232 http://id.nlm.nih.gov/mesh/M0021911 http://id.nlm.nih.gov/mesh/M0028918 http://id.nlm.nih.gov/mesh/M0493371
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D023241Q000379 http://id.nlm.nih.gov/mesh/D003510Q000493 http://id.nlm.nih.gov/mesh/D019380Q000493 http://id.nlm.nih.gov/mesh/D004347 http://id.nlm.nih.gov/mesh/D011724Q000493 http://id.nlm.nih.gov/mesh/D014230Q000493 http://id.nlm.nih.gov/mesh/D015658Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D019438Q000008 http://id.nlm.nih.gov/mesh/D011724Q000008 http://id.nlm.nih.gov/mesh/D003510Q000008 http://id.nlm.nih.gov/mesh/D019380Q000008 http://id.nlm.nih.gov/mesh/D011743 http://id.nlm.nih.gov/mesh/D014230Q000008 http://id.nlm.nih.gov/mesh/D009570 http://id.nlm.nih.gov/mesh/D010949Q000737 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D015337 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000077592 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID392622 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_0943bfb20a0e8ebccd479b74c7b652df http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3002977 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9765 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID193962 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_89d708279e197fec68596fc46bc48c90

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245295723 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242670894

Total number of triples: 68.